Xeris Biopharma Holdings, Inc. revises revenue guidance for the full year 2023. For the year, the company tightening revenue guidance from $155 million - $165 million to $160 million - $165 million, which is at the high end of company's original range.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.945 USD | +2.37% | +1.06% | -19.15% |
May. 09 | Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.15% | 282M | |
+30.61% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+14.72% | 239B | |
+9.82% | 210B | |
-7.40% | 200B | |
+8.12% | 167B | |
-1.42% | 161B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Revises Revenue Guidance for the Full Year 2023